Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

Press release Jun 19, 2018 OTC Disclosure & News Service Breakthrough Quantitative MIDS Testing Results VALENCIA, SPAIN, June 19, 2018; Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of…

Details

Zenosense, Inc.: MIDS Hybrid Strip – Successful Initial Test Results

Press release Nov 16, 2017 OTC Disclosure & News Service Zenosense, Inc.: MIDS Hybrid Strip – Successful Initial Test Results VALENCIA, SPAIN — (Marketwired) — 11/16/17 — Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld…

Details

Zenosense, Inc. — MIDS Hybrid Strip Detection Testing to Commence

Press release Jul 05, 2017 OTC Disclosure & News Service Zenosense, Inc. — MIDS Hybrid Strip Detection Testing to Commence VALENCIA, SPAIN–(Marketwired – Jul 5, 2017) – Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld…

Details

Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services

Press release Mar 28, 2017 OTC Disclosure & News Service Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services VALENCIA, SPAIN–(Marketwired – Mar 28, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld…

Details

Zenosense, Inc.: MIDS Quantitative Testing Results

Press release Mar 10, 2017 OTC Disclosure & News Service Zenosense, Inc.: MIDS Quantitative Testing Results VALENCIA, SPAIN–(Marketwired – Mar 10, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense,” the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection…

Details

Zenosense, Inc.: MIDS Quantitative Testing Commences

Press release Feb 22, 2017 OTC Disclosure & News Service Zenosense, Inc.: MIDS Quantitative Testing Commences VALENCIA, SPAIN–(Marketwired – Feb 22, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection…

Details

Zenosense, Inc.: New Patent Application for Additional MIDS Detection Method

Press release Jan 23, 2017 OTC Disclosure & News Service Zenosense, Inc.: New Patent Application for Additional MIDS Detection Method VALENCIA, SPAIN–(Marketwired – Jan 23, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device…

Details

Zenosense, Inc. MIDS Proof of Market Report

Press Release Nov 17, 2016 OTC Disclosure & News Service Zenosense, Inc. MIDS Proof of Market Report VALENCIA, SPAIN–(Marketwired – Nov 17, 2016) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early…

Details

Zenosense, Inc. MIDS Cardiac Bench Reader Development

Press Release VALENCIA, SPAIN–(Marketwired – Oct 31, 2016) –  Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition…

Details

Zenosense, Inc. General Update – Cardiac Device Development

VALENCIA, SPAIN–(Marketwired – Sep 19, 2016) –  Zenosense, Inc. ( OTC PINK : ZENO ) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialisation of MIDS Cardiac™, a Point of Care (“POC”) hand held device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis,…

Details